<div id="readability-page-1">08:12 AM EST, 12/29/2025 (MT Newswires) -- Zevra Therapeutics ( ZVRA ) said Monday that it has signed an exclusive, expanded access distribution agreement with Irish pharmaceutical services provider Uniphar.The agreement will enable reimbursed named patient supply of Miplyffa, Zevra's treatment for Niemann-Pick disease type C, in certain territories outside of Europe, the company said.Miplyffa, or arimoclomol, is approved in the US and under review by the European Medicines Agency, the company said.Shares of Zevra were up more than 1% in recent premarket activity Monday. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

ZVRA

Zevra Therapeutics has signed an exclusive distribution agreement with Uniphar for Miplyffa, its treatment for Niemann-Pick disease type C, allowing reimbursed supply in select territories outside Europe. Miplyffa is approved in the US and under review in Europe. Zevra's shares rose over 1% in premarket trading.

Zevra Therapeutics Signs Expanded Miplyffa Distribution Deal With Uniphar